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P2324: Atg12 maintains skeletal integrity by modulating pro-
osteoclastogenic signals and chondrocyte differentiation
INTRODUCTION
CONCLUSION
Loss of autophagy via Atg12 deletion (1) perturbs
signals that regulate bone homeostasis, favoring a pro-
osteoclastogenic environment, ultimately leading to net
bone loss and (2) disrupts chondrocyte proliferation and
differentiation. The male skeleton is more sensitive to
effects of autophagy deletion.
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RESULTS
Figure 5. (A) Representative cross sections generated by microCT showing reduced
cortical thickness (red rectangle). (B) MicroCT measurements of cortical thickness.
Two-way ANOVA indicate Treatment and Gender affects but no Treatment x Gender
effects; N=3-4. Error bars show SD. *Significant at p<0.05 compared to gender-
matched wild type (vehicle-treated) control by one-way ANOVA.
PURPOSE OF THE STUDY
Determine the consequences of global loss of Atg12 on
skeletal integrity and bone homeostasis; elucidate
underlying mechanisms.
Figure 1. Body mass of groups prior to
treatment. Male and females CAG-CreERT2/
Atg12flox/flox mice were divided into groups
that were to receive vehicle (WT) or
tamoxifen treatment (KO). Values depicted
are means; N=3-4/group. Error bars indicate
SD; Wild type and KO groups within a gender
had similar body weights at onset of
treatment. One-way ANOVA showed gender
effects in pre-treatment body weights.
Body mass and treatment effects
Atg12 deletion results in loss of structural integrity of
cortical bone; effects more prominent in males
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MATERIALS AND METHODS
Atg 12 knockout studies: 
Strain: CAG-CreERT2 / Atg12flox/flox in C57BL/6 background
Age at onset of Tamoxifen treatment: 6 weeks (1.5 months)
Age at euthanasia: 8 weeks
Samples collected: femora and tibiae
All animal procedures were performed with IACUC pre-
approval.
Quantitative PCR (qPCR): RNA extraction of femur was
performed using Trizol method and cDNA generated.
Relative gene expression levels were calculated using the
∆∆Ct method with Rpl19 as internal control.
Analysis of skeletal microarchitecture: Microcomputed
tomography of tibia was performed using Skyscan platform
(Bruker) at resolutions of 6.7 and 15 µm for cancellous and
cortical bone respectively.
Histology: Tissues were fixed in 4% paraformaldehyde and
processed for paraffin sectioning. Safranin O stain was
performed to visualize chondrocytes.
Abstract
Weightlessness and radiation, two unique elements of space, profoundly decreases bone mass. This
bone loss is attributed to increased activity of bone-resorbing osteoclasts and functional changes in
bone-forming osteoblasts, cells that give rise to mature osteocytes. Our long-term goal is to identify
signaling pathways that may be targeted to mitigate bone loss in scenarios of space exploration,
radiotherapy and accidental radiation exposure. We have previously shown that exposure of MLO-Y4
osteocyte-like cells to simulated space radiation (56Fe) increased the expression of the pro-
osteoclastogenic gene rankl and decreased protein levels of LC3B-II, a key player in autophagy. In
this current study, we aimed to further elucidate the role of autophagy in maintaining structural integrity
of the skeleton. We hypothesize that loss of autophagy in bone leads to an imbalance in pro-
osteoclastogenic and pro-osteogenic signals, resulting in net bone loss. To test our hypothesis we
performed global postnatal deletion of Atg12 using tamoxifen-inducible Cre recombinase under the
control of the CAG promoter. Six-week-old CAG-CreERT2/FloxAtg12 animals were treated daily with
Tamoxifen or Vehicle (Control, oil only) for five days and euthanasia performed two weeks after the
onset of treatment. Percent change in body weights (prior to treatment and at euthanasia) was not
significantly different between treatment groups within the same gender. Compared to Vehicle
(Control) groups, Tamoxifen (Atg12 iKO) groups showed decreased LC3B-I to II conversion and
increased p62 protein levels, consistent with loss of autophagy. Quantitative PCR revealed increased
expression of pro-osteoclastogenic cytokines mcp1 and rankl in bone and marrow respectively in male
iKOs compared to male controls. Expression levels of these genes were not significantly altered in the
Atg12 iKO females compared to females controls. Microcomputed tomography of tibiae revealed
decreased cortical bone volume, cortical thickness and periosteal perimeter consistent with bone loss;
and a longer primary spongiosa in male Atg12 iKOs compared to male controls. These decrements
were less pronounced in the female Atg12 iKOs. Cancellous bone structure was not significantly
different between iKOs and controls in both genders. Histological analysis also revealed that
compared to male controls, male iKOs showed a profound increase in chondrocyte column length of
the growth plate with hyper-expansion of both proliferating and hypertrophic zones. Taken together,
these findings indicate that autophagy plays an important role in the maintenance of bone structural
integrity by mediating the production of pro-osteoclastogenic signals and regulating chondrocyte
proliferation and differentiation.
Atg12 deletion favors a pro-osteoclastogenic environment
in bone and marrow in a gender-dependent manner
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Figure 3. Loss of autophagy after two weeks of tamoxifen treatment of CAG-
CreERT2 / Atg12flox/flox mice. Atg12 expression levels in (A) bone and (B) marrow two
weeks after onset of tamoxifen treatment. WT: Vehicle-treated; KO: Tamoxifen-
treated. Error bars show upper and lower ranges of relative gene expression levels.
*Significant at p<0.05 compared to gender-matched wild type (vehicle-treated)
control by two-way ANOVA and Tukey post-hoc test. (C) Western blot showing
profound accumulation of LC3B-I (red arrow) and impairments in its cleavage to
LC3B-II (black arrow) in bone of KO mice, confirming loss of autophagy. Equal
amounts of protein were loaded per well although actin levels appear to change in
response to loss of Atg12 (lower blot).
Efficiency of Atg12 deletion and confirmation of autophagy
impairment in bone
(A) Atg12 in bone
(A) Rankl in bone (B) Rankl in marrow
Cancellous bone is less sensitive to Atg12 deletion
Figure 6. (A) % bone volume (BV/TV) as
measured by microCT. Two-way ANOVA revealed
no significant treatment, gender or treatment x
gender effects although there was a tendency for
decreased BV/TV in male KO’s compared to wild
type males. A similar trend was observed for
trabecular thickness (data not shown).
Figure 4. qPCR analyses of Rankl expression in (A) bone and (B) marrow; (C)
Mcp1 expression in bone. WT: Vehicle-treated; KO: Tamoxifen-treated. Boxes
below graphs indicate results of two-way ANOVA with significance set at p<0.05.
NS: Not significant. Error bars show upper and lower ranges of relative gene
expression levels. *Significant at p<0.05 compared to gender-matched wild type
(vehicle-treated) control by two-way ANOVA and Tukey post-hoc test. (D) Rankl
encodes a surface-bound molecule on osteoblasts (and osteocytes) that activates
osteoclasts. OPG is a decoy receptor that sequesters RANKL and prevents it from
binding to its true receptor on osteoclasts, thereby inhibiting osteoclast activity.
Atg12 deletion leads to altered chondrocyte structure in the
growth plate
Figure 7. (A) MicroCT image
showing that Atg12 deletion
leads to expansion of region
(red bracket) on growth plate
where chondrocytes reside. (B)
Safranin O staining confirms
that Atg12 deletion results in
longer chondrocyte columns
(yellow lines) and expanded
stacks of hypertrophic chondro-
cytes (white lines).
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Major cell types involved in skeletal homeostasis
Molecular mechanisms of bone loss
Underlying mechanisms include increase in pro-
osteoclastogenic (pro-resorption) signals and increased
reactive oxygen species (ROS) with resulting oxidative
stress in bone. Accumulation of oxidative damage in
osteoblasts and osteocytes can lead to cell death, which in
turn may also contribute to bone loss.
Role of autophagy in bone
Macroautophagy (referred to here as “autophagy”) is a
process by which organelles are broken down and recycled
for use in new cellular components and signaling events.
Deletion of Atg7 in osteocytes leads to osteopenia (Onal et
al. 2013).
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Figure 2. Percent change in body mass
calculated at onset (Pre) and day 4 of (T4) of
tamoxifen treatment of CAG-CreERT2/
Atg12flox/flox mice. WT: vehicle-treated; KO:
tamoxifen-treated. Values depicted are
means; N=3-4/group. Error bars indicate SD.
% change = 100 x (MassT4 – MassPre)/MassPre
Two-way ANOVA indicates no gender and
treatment effects on % change in body mass.
Treatment: not significant
Gender: not significant
Treatment x Gender: not significant
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(C) Mcp1 in bone
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(D) RANKL signaling
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(A) Cross-section of mouse tibia, males
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(B) Cortical thickness
(A) Osteoclasts attach to
bone surface to resorb bone.
Osteoblasts come onto site
of resorption. As osteoblasts
mature, they lay out mineral
and embed into bone to
become osteocytes.
(B) Excess resorption
relative to bone formation
leads to bone loss.
Tamoxifen or Vehicle 
(oil) by oral gavage
1 2 3 4 5 14
Euthanasia
Days
*
0.0
0.1
0.2
0.3
Male Female
WT KO
C
t. 
Th
., 
m
m
0.0
5.0
10.0
15.0
20.0
Male Female
WT KO
https://ntrs.nasa.gov/search.jsp?R=20180008606 2019-08-31T17:51:19+00:00Z
